VIDEO: Remission rates comparable with shorter venetoclax regimen in AML
NEW ORLEANS — In this video, Aaron T. Gerds, MD, MS, discusses a study presented at the ASH Annual Meeting and Exposition, which evaluated a 7-day regimen of venetoclax and azacytidine in patients with treatment-naive acute myeloid leukemia.
The study found the 7-day dosing regimen to be efficient compared with a regimen of 7 days of azacytidine and 28 days of venetoclax as outlined in the VIALE-A protocol.
Gerds, assistant professor at the Cleveland Clinic Taussig Cancer Institute, described the 28-day venetoclax regimen as “a pretty toxic combination for most patients.”
“This particular abstract looked at a course of 7 days, which is significantly shorter than the 28 days, but still saw remission rates comparable to the VIALE-A trial, so I thought that was very provocative,” Gerds said.
"It tells me that we still have a long way to go to understand how to best use venetoclax in AML," he said.
References:
- Willekens C, et al. Oral 222. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans
Collapse
Healio Interviews
Read more about